Puma Biotechnology, Inc. (NASDAQ:PBYI)‘s shares have oscillated between a high of $-5.35% and a low of $150.95% over the last 12 months.
For the last 50 days, the stock has risen to a peak price of $52.62% and hit a bottom of $144.62%.
The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching overbought territory. Be watchful of a trend reversal.
Recently, Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that the U.S. Food and Drug Administration (FDA) posted briefing documents on its website in preparation for the May 24 Oncologic Drugs Advisory Committee (ODAC) meeting scheduled to review PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer.
On moving volumes measurements, the stock?s 20-Day Simple Moving Average price is $96.15%, 50-Day Simple Moving Average is $85.35% and 200-Day Simple Moving Average is $61.98%.
The stock is now moved 23.13% for the year. Over the last six months it has moved -9.57%, compared with a movement of -6.09% for the quarter, 0.40% for the month and 17.21%% for the week.
The average volume, usually a measurement of three months average, is 1.12M. Relative volume on the other hand is 9.70. In total, Puma Biotechnology, Inc. has 37.65M shares outstanding, with 31.82M of them being free float shares.
The stock?s short float stands at 24.97%, working out to a short ratio of 7.11.
Institutional investors own 95.30% of Puma Biotechnology, Inc.?s equity, while insiders own 11.60% of the stock. In the last couple of months, the stock has seen 9.87% institutional investor transactions, compared to -0.48% insider transactions.
How have the investors seen their investment in the stock change? Puma Biotechnology, Inc.’s return on equity for the trailing 12 months is -186.70%. The company posted return on assets of -143.60% for the same trailing 12 months period.
Does Puma Biotechnology, Inc. have the ability to keep its doors open ? at least over the short-term? The company’s current ratio at the end of the most recent quarter was 4.70, while quick ratio for the same period was 4.70.
For the matters of debt, the company’s Long Term Debt/Equity for the most recent quarter was 0.00 and Total Debt/Equity for the same period was 0.00.